瑞舒伐他汀联合非诺贝特治疗混合性高脂血症疗效与安全性观察  

Efficacy and Safety of Combination Therapy with Rosuvastatin and Fenofibrate for Combined Hyperlipidemia

作　　者：于姝姝 刘奇良[1] YU Shu-shu LIU Qi-liang.(Department of Cardiology, People＇s Hospital of Putuo District, Shanghai 200060, Chin)

机构地区：[1]上海市普陀区人民医院心内科,上海200060

出　　处：《医学与哲学（B）》2017年第6期28-30,60,共4页Medicine & Philosophy(B)

摘　　要：为了探讨瑞舒伐他汀与非诺贝特联合治疗混合性高脂血症疗效与安全性,选取152例混合性高脂血症患者,随机分为瑞舒伐他汀组(n=50),非诺贝特组(n=49),两药联合组(n=53)。比较三组调脂水平、不良反应情况。结果显示联合组调脂能力明显高于单药组(P值小于0.01或0.05)。联合组调脂达标率明显高于单药组(P<0.05)。联合组安全性良好,不良反应发生率同另外两组相比差异无统计学意义(P值均>0.05)。因此,联合组具有安全、高效的调脂能力。The aim of this study was to evaluate efficacy and safety of combination therapy with rosuvastatin and fenofibrate.A total of 152 patients with combined hyperlipidemia were randomly assigned to fenofibrate（n=49）,rosuvastatin（n=50）,or a combination therapy（n=53）.Lipid profiles,rate of reaching the standard and untoward effect were assessed.Results display the reducing in TG and improvement in HDL-C achieved by combination treatment was superior to fenofibrateor rosuvastatin alone.The success rate in the combination therapy group was superior to fenofibrateor rosuvastatin alone.All treatments were well tolerated with no increase in adverse events for combination therapy versus monotherapy.So the results of this study demonstrated that combination therapy is more effective and safe.

关 键 词：降血脂 联合药物治疗 瑞舒伐他汀 非诺贝特 

分 类 号：R54[医药卫生—心血管疾病]